15 May 2017 - The EMA has published a draft agenda for this week's CHMP meeting.

The CHMP is scheduled to give initial opinions on the following initial applications:

• Anamorelin
  
• Rituximab
  
• Efavirenz with emtricitabine and tenofovir disoproxil fumarate
  
• Human IgG1 monoclonal antibody specific for human interleukin-1 alfa
  
• Insulin lispro
  
• Brodalumab
  
• Masitinib mesylate
  
• Etirinotecan pegol
  
• Cenegermin
  
• Cariprazine
  
• Rituximab
  
• Spheroids of human autologous matrix-associated chondrocytes
  
• Beclometasone dipropionate with eformoterol fumarate dihydrate and glycopyrronium bromide
  
• Rituximab
  
• Patiromer sorbitex calcium
  

Read CHMP draft agenda